Published in Mol Cell Biol on July 01, 2004
The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest (2005) 2.62
For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer (2010) 2.26
Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood (2005) 2.09
The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med (2005) 1.99
Gene function in early mouse embryonic stem cell differentiation. BMC Genomics (2007) 1.96
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma (2008) 1.91
PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica (2010) 1.83
Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. BMC Cell Biol (2006) 1.72
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev (2011) 1.70
Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med (2009) 1.52
De-novo identification of PPARgamma/RXR binding sites and direct targets during adipogenesis. PLoS One (2009) 1.39
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood (2009) 1.28
Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase. Proc Natl Acad Sci U S A (2013) 1.27
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood (2013) 1.26
EPO receptor circuits for primary erythroblast survival. Blood (2008) 1.26
mTOR at the crossroads of T cell proliferation and tolerance. Semin Immunol (2007) 1.22
The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A (2010) 1.20
In vivo identification of novel STAT5 target genes. Nucleic Acids Res (2008) 1.19
Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions. J Med Genet (2005) 1.18
Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood (2007) 1.16
Why target PIM1 for cancer diagnosis and treatment? Future Oncol (2010) 1.12
Elevated levels of oncogenic protein kinase Pim-1 induce the p53 pathway in cultured cells and correlate with increased Mdm2 in mantle cell lymphoma. J Biol Chem (2008) 1.09
Nuclear and mitochondrial signalling Akts in cardiomyocytes. Cardiovasc Res (2009) 1.09
Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood (2012) 1.07
JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol (2007) 1.05
Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene (2011) 1.02
KSHV reactivation from latency requires Pim-1 and Pim-3 kinases to inactivate the latency-associated nuclear antigen LANA. PLoS Pathog (2009) 1.01
The direct Myc target Pim3 cooperates with other Pim kinases in supporting viability of Myc-induced B-cell lymphomas. Oncotarget (2011) 1.00
Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PLoS One (2009) 0.99
Context-specific BAFF-R signaling by the NF-κB and PI3K pathways. Cell Rep (2013) 0.99
PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther (2015) 0.97
Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood (2012) 0.96
Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation. Immunology (2005) 0.95
A potential therapeutic target for FLT3-ITD AML: PIM1 kinase. Leuk Res (2011) 0.94
Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. PLoS One (2013) 0.92
Genetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens. Front Oncol (2014) 0.92
Metabolic dysfunction consistent with premature aging results from deletion of Pim kinases. Circ Res (2014) 0.88
Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication. PLoS One (2013) 0.88
Pim-2 phosphorylation of p21(Cip1/WAF1) enhances its stability and inhibits cell proliferation in HCT116 cells. Int J Biochem Cell Biol (2010) 0.88
Lymphocyte development: integration of DNA damage response signaling. Adv Immunol (2012) 0.87
MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine. Oncotarget (2015) 0.87
Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells (2013) 0.87
Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk (2013) 0.87
Normal T-cell development and immune functions in TRIM-deficient mice. Mol Cell Biol (2006) 0.87
Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling. J Mol Cell Cardiol (2011) 0.86
PIM1 kinase phosphorylates the human transcription factor FOXP3 at serine 422 to negatively regulate its activity under inflammation. J Biol Chem (2014) 0.86
Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing. Oncogene (2014) 0.86
p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res (2010) 0.85
Targeting the Pim kinases in multiple myeloma. Blood Cancer J (2015) 0.84
Detecting recurrent gene mutation in interaction network context using multi-scale graph diffusion. BMC Bioinformatics (2013) 0.84
Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal (2014) 0.84
The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget (2014) 0.84
Pim-selective inhibitor DHPCC-9 reveals Pim kinases as potent stimulators of cancer cell migration and invasion. Mol Cancer (2010) 0.83
Association of single nucleotide polymorphisms in PIM-1 gene with the risk of Korean lung cancer. Cancer Res Treat (2008) 0.83
Pathophysiological roles of Pim-3 kinase in pancreatic cancer development and progression. World J Gastroenterol (2014) 0.82
Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol (2013) 0.82
STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells. JAKSTAT (2012) 0.81
The role of suppressors of cytokine signalling in human neoplasms. Mol Biol Int (2014) 0.81
Activation of cell cycle arrest and apoptosis by the proto-oncogene Pim-2. PLoS One (2012) 0.81
Inhibition of Pim1 kinase activation attenuates allergen-induced airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol (2011) 0.81
Accelerated evolution of PAK3- and PIM1-like kinase gene families in the zebra finch, Taeniopygia guttata. Mol Biol Evol (2010) 0.81
JunD/AP-1-mediated gene expression promotes lymphocyte growth dependent on interleukin-7 signal transduction. PLoS One (2012) 0.81
A regulatory feedback loop between HIF-1α and PIM2 in HepG2 cells. PLoS One (2014) 0.80
Proviral integration site for Moloney murine leukemia virus (PIM) kinases promote human T helper 1 cell differentiation. J Biol Chem (2012) 0.80
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med (2016) 0.80
Pim kinases in hematological malignancies: where are we now and where are we going? J Hematol Oncol (2014) 0.79
Pim Kinases Promote Migration and Metastatic Growth of Prostate Cancer Xenografts. PLoS One (2015) 0.79
Tricyclic Benzo[cd]azulenes selectively inhibit activities of Pim kinases and restrict growth of Epstein-Barr virus-transformed cells. PLoS One (2013) 0.78
Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. PLoS One (2013) 0.78
Proviral integration site 2 is required for interleukin-6 expression induced by interleukin-1, tumour necrosis factor-α and lipopolysaccharide. Immunology (2010) 0.78
Inhibition of Pim-1 kinase ameliorates dextran sodium sulfate-induced colitis in mice. Dig Dis Sci (2012) 0.77
Integrated signaling in developing lymphocytes: the role of DNA damage responses. Cell Cycle (2012) 0.77
Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. Oncotarget (2014) 0.77
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. Oncotarget (2015) 0.77
Pim-2 Kinase Influences Regulatory T Cell Function and Stability by Mediating Foxp3 Protein N-terminal Phosphorylation. J Biol Chem (2015) 0.77
Pim3 negatively regulates glucose-stimulated insulin secretion. Islets (2010) 0.77
Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase. Acta Crystallogr Sect F Struct Biol Cryst Commun (2004) 0.76
Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition. Oncotarget (2016) 0.75
Developmental stage-specific effects of Pim-1 dysregulation on murine bone marrow B cell development. BMC Immunol (2016) 0.75
Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors. ACS Med Chem Lett (2014) 0.75
Novel molecular mechanism for generating NK-cell fitness and memory. Eur J Immunol (2015) 0.75
Design and Synthesis of Potent and Selective PIM Kinase Inhibitors by Targeting Unique Structure of ATP-Binding Pocket. ACS Med Chem Lett (2017) 0.75
In vitro characterization of the RS motif in N-terminal head domain of goldfish germinal vesicle lamin B3 necessary for phosphorylation of the p34cdc2 target serine by SRPK1. FEBS Open Bio (2013) 0.75
Human CD180 Transmits Signals via the PIM-1L Kinase. PLoS One (2015) 0.75
Pim1 kinase regulates c-Kit gene translation. Exp Hematol Oncol (2016) 0.75
Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors. PLoS One (2012) 0.75
Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447. Oncotarget (2016) 0.75
Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling. Oncotarget (2016) 0.75
PIM1 induces cellular senescence through phosphorylation of UHRF1 at Ser311. Oncogene (2017) 0.75
Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma. Leukemia (2017) 0.75
Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus. Oncotarget (2017) 0.75
PIM1: a promising target in patients with triple-negative breast cancer. Med Oncol (2017) 0.75
Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer? Cold Spring Harb Mol Case Stud (2017) 0.75
B cell development pathways. Annu Rev Immunol (2001) 6.94
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell (1984) 5.56
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Dicistronic targeting constructs: reporters and modifiers of mammalian gene expression. Proc Natl Acad Sci U S A (1994) 4.44
High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet (2002) 3.81
The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev (2003) 3.79
Consecutive inactivation of both alleles of the pim-1 proto-oncogene by homologous recombination in embryonic stem cells. Nature (1990) 3.57
Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity (1999) 3.53
STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J (1999) 3.14
Gamma chain required for naïve CD4+ T cell survival but not for antigen proliferation. Nat Immunol (2000) 3.10
Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas. EMBO J (1985) 2.47
Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity (1999) 2.31
The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J (1991) 2.26
Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem (1988) 2.19
Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol (1991) 2.06
Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood (1999) 1.97
Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. Am J Respir Cell Mol Biol (2001) 1.78
The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene (1999) 1.59
Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2. EMBO J (1995) 1.55
Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene (1997) 1.45
In vivo analysis of Pim-1 deficiency. Nucleic Acids Res (1993) 1.40
Complementation tagging of cooperating oncogenes in knockout mice. Semin Cancer Biol (1996) 1.37
Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene (2000) 1.26
Induction of pre-B cell proliferation after de novo synthesis of the pre-B cell receptor. Proc Natl Acad Sci U S A (2001) 1.24
Signaling by the cytokine receptor superfamily. Ann N Y Acad Sci (1998) 1.22
Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. Oncogene (1992) 1.19
Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death. Oncogene (2000) 1.19
Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis. Blood (2002) 1.16
Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor. Blood (1995) 1.16
Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood (1994) 1.16
Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/lpr mice. Proc Natl Acad Sci U S A (1993) 1.15
Lifespan of lymphocytes. Immunol Res (1995) 1.14
PIM1 reconstitutes thymus cellularity in interleukin 7- and common gamma chain-mutant mice and permits thymocyte maturation in Rag- but not CD3gamma-deficient mice. J Exp Med (1999) 1.13
Pim-1 levels determine the size of early B lymphoid compartments in bone marrow. J Exp Med (1993) 1.12
Insulin-like growth factor-1 potentiates expansion of interleukin-7-dependent pro-B cells. Blood (1993) 1.12
Impaired interleukin-3 response in Pim-1-deficient bone marrow-derived mast cells. Blood (1993) 1.11
KID-1, a protein kinase induced by depolarization in brain. J Biol Chem (1998) 1.08
Identification of the human pim-1 gene product as a 33-kilodalton cytoplasmic protein with tyrosine kinase activity. Mol Cell Biol (1988) 1.05
pim-1 proto-oncogene expression in anti-CD3-mediated T cell activation is associated with protein kinase C activation and is independent of Raf-1. J Immunol (1996) 0.96
Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch Biochem Biophys (2001) 0.95
Identification and characterization of collaborating oncogenes in compound mutant mice. Cancer Res (1999) 0.94
Expression and function of insulin-like growth factor receptors on anti-CD3-activated human T lymphocytes. J Immunol (1992) 0.94
Identification of the autophosphorylation sites of the Xenopus laevis Pim-1 proto-oncogene-encoded protein kinase. J Biol Chem (1997) 0.89
Targeted gene mutations define the roles of insulin and IGF-I receptors in mouse embryonic development. J Pediatr Endocrinol Metab (1999) 0.88
The human Pim-2 proto-oncogene and its testicular expression. Biochim Biophys Acta (1998) 0.87
Prolactin regulation of pim-1 expression: positive and negative promoter elements. Endocrinology (1999) 0.84
53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol (2010) 5.59
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A (2008) 4.61
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet (2002) 3.81
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell (2003) 3.31
p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature (2007) 3.26
Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell (2008) 3.25
Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 3.24
Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci U S A (2005) 2.81
American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology (2008) 2.79
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov (2012) 2.74
Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology (2012) 2.68
Rnf2 (Ring1b) deficiency causes gastrulation arrest and cell cycle inhibition. Proc Natl Acad Sci U S A (2003) 2.67
Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell (2011) 2.63
Mouse models for human lung cancer. Genes Dev (2005) 2.59
Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice. Nat Genet (2002) 2.53
Conditional mouse models of sporadic cancer. Nat Rev Cancer (2002) 2.47
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39
Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med (2007) 2.39
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell (2011) 2.35
A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. Cancer Cell (2011) 2.29
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res (2008) 2.27
For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer (2010) 2.26
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer (2012) 2.20
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res (2005) 2.19
Chromatin position effects assayed by thousands of reporters integrated in parallel. Cell (2013) 2.16
Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics (2007) 2.15
MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat Genet (2007) 2.14
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res (2003) 2.07
High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer (2009) 2.06
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02
A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc (2009) 1.95
Mutagenic insertion and chromosome engineering resource (MICER). Nat Genet (2004) 1.88
Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci U S A (2002) 1.85
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res (2009) 1.82
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol (2010) 1.76
The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol (2015) 1.68
Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development (2004) 1.65
PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development (2002) 1.64
Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Res (2008) 1.63
NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J (2008) 1.62
Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. J Pathol (2011) 1.61
How do real tumors become resistant to cisplatin? Cell Cycle (2008) 1.60
Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland. J Pathol (2012) 1.57
Cell of origin of lung cancer. Mol Oncol (2010) 1.54
Oncogene addiction: sometimes a temporary slavery. Cancer Cell (2004) 1.54
Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. Nucleic Acids Res (2008) 1.52
Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol (2009) 1.47
Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res (2002) 1.46
Knockout mouse models to study Wnt signal transduction. Trends Genet (2006) 1.46
Bmi1 regulates stem cells and proliferation and differentiation of committed cells in mammary epithelium. Curr Biol (2008) 1.45
Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene (2004) 1.44
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res (2009) 1.44
BRCA2 acts as a RAD51 loader to facilitate telomere replication and capping. Nat Struct Mol Biol (2010) 1.44
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res (2008) 1.42
Fast handheld two-photon fluorescence microendoscope with a 475 microm x 475 microm field of view for in vivo imaging. Opt Lett (2008) 1.41
What makes tumors multidrug resistant? Cell Cycle (2007) 1.34
Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry (2006) 1.33
Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33
A whole-genome mouse BAC microarray with 1-Mb resolution for analysis of DNA copy number changes by array comparative genomic hybridization. Genome Res (2004) 1.32
Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res (2006) 1.31
Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci U S A (2014) 1.30
BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. J Exp Med (2013) 1.30
Targeted gene modification in mismatch-repair-deficient embryonic stem cells by single-stranded DNA oligonucleotides. Nucleic Acids Res (2003) 1.28
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res (2013) 1.28
Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J (2002) 1.26
Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. Cancer Res (2005) 1.26
The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res (2003) 1.19
Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med (2012) 1.19
A self-assembled multimodal complex for combined pre- and intraoperative imaging of the sentinel lymph node. Nanotechnology (2010) 1.18
Mouse models for lung cancer. Mol Oncol (2013) 1.18
Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res (2009) 1.18
A high-throughput functional complementation assay for classification of BRCA1 missense variants. Cancer Discov (2013) 1.17
Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med (2014) 1.17
Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech (2011) 1.16
Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol (2007) 1.16
Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells. Oncogene (2002) 1.16
Further evidence for BRCA1 communication with the inactive X chromosome. Cell (2007) 1.15
Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res (2009) 1.15
A conditional mouse model for malignant mesothelioma. Cancer Cell (2008) 1.14
Autonomic function is impaired in elderly stroke survivors. Stroke (2005) 1.13
DCC expression by neurons regulates synaptic plasticity in the adult brain. Cell Rep (2013) 1.13
Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest (2011) 1.13
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. Cell Cycle (2008) 1.12
Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist Updat (2007) 1.12